Digital health to save $100B over next four years

FDA-regulated digital health solutions are expected to save the U.S. healthcare system about $100 billion over the next four years, according to research released by Accenture. 

“A digital disruption is playing out in healthcare, as witnessed by the emergence of new business models and technology that will change the nature of patient interactions, alter consumer expectations and ultimately improve health outcomes,” said Rick Ratliff, managing director of Accenture's digital health solutions.
 
The company estimates that such tools achieved $6 billion in cost savings in 2014, primarily driven by medication adherence, behavior modifications and fewer emergency room visits. Accenture expects that figure to rise to $10 billion in 2015, $18 billion in 2016, $30 billion in 2017 and $50 billion in 2018, and also predicts that FDA approvals of digital health solutions will triple by the end of 2018, to 100, from 33 last year.

Regulatory guidelines for low-risk devices that provide more clarity around FDA oversight and expedited regulatory pathways are responsible for some of the growth, along with higher rates of health IT adoption among providers, increasing demand for self-management of care and the transition to value-based payment models.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.